A new study suggests Oncotype DX-guided treatment could reduce the cost for the first year of breast cancer care in the U.S. by about $50 million—about 2% of the overall costs in the first year. The study, conducted by Georgetown Lombardi Comprehensive Cancer Center and NCI researchers, was published in JNCI.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
